As Sanofi posts yet another stellar set of sales figures for its autoimmune mega-blockbuster Dupixent, CEO Paul Hudson has told Scrip that growth is set to keep soaring despite the arrival of competition in the US from oral JAK inhibitors in its key indication of atopic dermatitis.
The French major's fourth-quarter revenues of €9.99bn (+4.1%) were dominated yet again by Regeneron Pharmaceuticals, Inc.-partnered Dupixent (dupilumab) which...








